Antibe Therapeutics Inc (ATE) Director Acquires C$11,900.00 in Stock
Antibe Therapeutics Inc (CVE:ATE) Director Daniel Marcel Legault bought 35,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of C$0.34 per share, for a total transaction of C$11,900.00. Following the completion of the acquisition, the director now owns 265,000 shares in the company, valued at approximately C$90,100.
Shares of CVE:ATE traded up C$0.01 during mid-day trading on Wednesday, hitting C$0.34. 23,911 shares of the company traded hands, compared to its average volume of 540,813. The company has a market cap of $82.66 million and a P/E ratio of -6.20. The company has a debt-to-equity ratio of 35.82, a quick ratio of 2.10 and a current ratio of 3.77. Antibe Therapeutics Inc has a 52-week low of C$0.24 and a 52-week high of C$0.46.
Antibe Therapeutics (CVE:ATE) last announced its earnings results on Friday, February 15th. The company reported C($0.01) EPS for the quarter, meeting the consensus estimate of C($0.01). The company had revenue of C$2.50 million for the quarter, compared to analysts’ expectations of C$2.20 million. Analysts predict that Antibe Therapeutics Inc will post -0.0299999982352942 earnings per share for the current year.
Antibe Therapeutics Company Profile
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.
Featured Article: Calculating net profit and net profit margin ratio
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.